› 5k6i

X-ray diffraction
2.92Å resolution

Crystal structure of prefusion-stabilized RSV F single-chain 9-10 DS-Cav1 A149C-Y458C, S46G-E92D-S215P-K465Q variant.

Released:
DOI: 10.2210/pdb5k6i/pdb
PDB entry 5k6i coloured by chain, front view.
PDB entry 5k6i coloured by chain, side view.
PDB entry 5k6i coloured by chain, top view.
Source organism: Human respiratory syncytial virus A2
Primary publication:
Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV.
Joyce MG, Zhang B, Ou L, Chen M, Chuang GY, Druz A, Kong WP, Lai YT, Rundlet EJ, Tsybovsky Y, Yang Y, Georgiev IS, Guttman M, Lees CR, Pancera M, Sastry M, Soto C, Stewart-Jones GBE, Thomas PV, Van Galen JG, Baxa U, Lee KK, Mascola JR, Graham BS, Kwong PD
OpenAccess logo Nat Struct Mol Biol 23 811-820 (2016)
PMID: 27478931

Function and Biology Details

Biochemical function:
  • not assigned
Biological process:
Cellular component:
  • not assigned
Sequence domain:

Structure analysis Details

Assembly composition:
homo trimer (preferred)
Assembly name:
PDBe Complex ID:
PDB-CPX-136982 (preferred)
Entry contents:
1 distinct polypeptide molecule
Macromolecule:
Fusion glycoprotein F1 Chain: F
Molecule details ›
Chain: F
Length: 445 amino acids
Theoretical weight: 49.18 KDa
Source organism: Human respiratory syncytial virus A2
Expression system: Homo sapiens
UniProt:
  • Canonical: P03420 (Residues: 26-103, 145-509; Coverage: 81%)
Gene name: F
Sequence domains: Fusion glycoprotein F0

Ligands and Environments

4 bound ligands:
Ligand ZN 2 x ZN
Ligand EDO 2 x EDO
Ligand PO4 1 x PO4
Ligand NAG 2 x NAG
No modified residues

Experiments and Validation Details

Entry percentile scores
X-ray source: APS BEAMLINE 22-ID
Spacegroup: P4132
Unit cell:
a: 169.561Å b: 169.561Å c: 169.561Å
α: 90° β: 90° γ: 90°
R-values:
R R work R free
0.221 0.22 0.253
Expression system: Homo sapiens

Quick links

Citations

32 review citations

Structure-Based Vaccine Antigen Design.
Graham et al. (2019)
31 more

5 mentions without citation

Iterative structure-based improvement of a fusion-glycoprotein vaccine against RSV.
Joyce et al. (2016)
4 more